Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note issued on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Up 0.8 %

CPIX stock opened at $1.26 on Thursday. Cumberland Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $2.36. The business’s 50 day simple moving average is $1.31 and its 200 day simple moving average is $1.46. The company has a current ratio of 1.44, a quick ratio of 1.26 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $17.88 million, a PE ratio of -2.14 and a beta of 0.20.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.